Skylands Capital LLC Sells 63,500 Shares of Elanco Animal Health Incorporated (NYSE:ELAN)

Skylands Capital LLC reduced its stake in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 15.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 353,950 shares of the company’s stock after selling 63,500 shares during the quarter. Skylands Capital LLC’s holdings in Elanco Animal Health were worth $5,274,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Sapient Capital LLC purchased a new stake in shares of Elanco Animal Health in the fourth quarter worth about $2,046,000. Phocas Financial Corp. bought a new position in shares of Elanco Animal Health during the 4th quarter valued at approximately $3,857,000. Ancora Advisors LLC bought a new position in shares of Elanco Animal Health during the 3rd quarter valued at approximately $37,189,000. UBS Group AG grew its holdings in shares of Elanco Animal Health by 78.2% in the third quarter. UBS Group AG now owns 681,905 shares of the company’s stock valued at $7,665,000 after purchasing an additional 299,166 shares in the last quarter. Finally, Raymond James & Associates increased its position in Elanco Animal Health by 210.9% in the third quarter. Raymond James & Associates now owns 1,015,294 shares of the company’s stock worth $11,412,000 after purchasing an additional 688,779 shares during the last quarter. Institutional investors own 97.48% of the company’s stock.

Insider Activity at Elanco Animal Health

In related news, Director R David Hoover purchased 20,000 shares of the firm’s stock in a transaction dated Wednesday, March 6th. The stock was purchased at an average price of $16.14 per share, with a total value of $322,800.00. Following the completion of the purchase, the director now owns 185,000 shares of the company’s stock, valued at approximately $2,985,900. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. 0.57% of the stock is currently owned by company insiders.

Elanco Animal Health Trading Up 3.3 %

Shares of ELAN traded up $0.44 during mid-day trading on Monday, reaching $13.70. 2,239,584 shares of the company’s stock traded hands, compared to its average volume of 4,359,948. The company has a current ratio of 2.75, a quick ratio of 1.35 and a debt-to-equity ratio of 0.92. The stock’s 50-day moving average is $15.36 and its two-hundred day moving average is $13.82. Elanco Animal Health Incorporated has a 12 month low of $7.88 and a 12 month high of $16.88.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings data on Monday, February 26th. The company reported $0.08 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.02). Elanco Animal Health had a negative net margin of 27.87% and a positive return on equity of 6.44%. The business had revenue of $1.04 billion during the quarter, compared to the consensus estimate of $1 billion. During the same period last year, the company earned $0.19 EPS. The business’s revenue was up 5.1% compared to the same quarter last year. On average, equities analysts anticipate that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts have commented on ELAN shares. Morgan Stanley increased their price objective on shares of Elanco Animal Health from $16.00 to $17.00 and gave the company an “overweight” rating in a research report on Tuesday, February 27th. The Goldman Sachs Group lifted their price target on Elanco Animal Health from $12.50 to $14.00 and gave the stock a “sell” rating in a research report on Tuesday, February 27th. TheStreet upgraded Elanco Animal Health from a “d+” rating to a “c-” rating in a research report on Friday, February 23rd. Barclays lifted their target price on Elanco Animal Health from $18.00 to $19.00 and gave the stock an “overweight” rating in a report on Tuesday, February 27th. Finally, Stifel Nicolaus upgraded Elanco Animal Health from a “hold” rating to a “buy” rating and raised their price target for the stock from $13.00 to $20.00 in a research report on Friday, January 5th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $16.71.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.